Incyte Corporation
INCY Healthcare Biotechnology
Incyte Corporation’s revenue for fiscal 2025 (year ended December 2025) was $5.1 billion, up 21.2% from fiscal 2024. In the quarter to June 2026, revenue grew 37.7%, EPS grew 39.7%, free cash flow grew 1,829.5% and total debt fell 10.5%, each against the same quarter a year earlier. Member of the S&P 500; revenue growth for ten consecutive years.
Follow INCY
Incyte Corporation (INCY) Return on equity
Incyte Corporation's return on equity over the twelve months to 30 June 2026 was 30.7%, up 0.8 percentage points from fiscal 2025 (29.9%). Over the past ten years it has ranged from −30.6% (fiscal 2017) to 35.3% (fiscal 2016); the current reading is higher than 91% of that period. That is above the Biotechnology industry median of −54.1% and above the Healthcare sector median of −28.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | 29.9% | 29.11 |
| FY2024 | 0.76% | (11.74) |
| FY2023 | 12.5% | 4.13 |
| FY2022 | 8.37% | (21.36) |
| FY2021 | 29.7% | 41.08 |
| FY2020 | −11.4% | (31.11) |
| FY2019 | 19.8% | 13.60 |
| FY2018 | 6.16% | 36.71 |
| FY2017 | −30.6% | (65.84) |
| FY2016 | 35.3% | 20.70 |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| ASND Ascendis Pharma A/S compare | 118.4% |
| ALNY Alnylam Pharmaceuticals, Inc. compare | 96.6% |
| EXEL Exelixis, Inc. compare | 44.4% |
| INCY Incyte Corporation | 30.7% |
| GMAB Genmab A/S Sponsored ADR compare | 14.0% |
| RPRX Royalty Pharma PLC compare | 8.42% |
| ROIV Roivant Sciences Ltd. compare | −5.47% |
| BNTX BioNTech SE Sponsored ADR compare | −9.53% |
| INSM Insmed, Inc. compare | −87.2% |
| Biotechnology industry median | −54.1% |
| Healthcare sector median | −28.3% |
| Market median | 1.35% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on INCY
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement